{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:29:21Z","timestamp":1793212161138,"version":"4.5.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Health and Labour Sciences Research Grants for Research on Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Janus kinase inhibitors (JAKis) have revolutionized ulcerative colitis (UC) management; however, the consequences of treatment discontinuation in patients achieving clinical remission remain poorly understood. This study investigated the clinical outcomes following JAKi discontinuation and retreatment effectiveness in patients with relapse.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this multicenter retrospective cohort study, we analyzed 101 patients with UC who received their first JAKi treatment between 2018 and 2024. Among them, 53 who achieved remission (Patient-Reported Outcome 2\u2005=\u20050) in week 8 were included. The primary endpoint was a comparison of relapse-free survival between the treatment continuation and discontinuation groups (n\u2005=\u200537 and 16, respectively). The secondary endpoints included assessment of post-discontinuation remission maintenance and post-retreatment remission rates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The proportion of female patients in the discontinuation group (68.8%) was higher (P\u2005=\u2005.0478) than the continuation group (40.5%). The mean relapse-free survival was significantly longer in the continuation group than in the discontinuation group (1679 vs 882 days, cumulative relapse-free rate 83.3% vs 13.6%, P\u2005&amp;lt;\u2005.001, respectively). In the latter, 13 patients experienced relapse during follow-up (post-discontinuation mean relapse-free survival: 326 days), although all patients remained in clinical and biological remission. Notably, among patients who received JAKi retreatment, 83.3% achieved remission in week 8.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>To our knowledge, this is the first real-world study to evaluate the effects of JAKi discontinuation on the outcomes for patients with UC. JAKi discontinuation in patients in remission was associated with a high relapse risk. JAKi retreatment was highly effective in patients who experienced relapse after treatment discontinuation, providing valuable evidence for managing treatment interruption.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/crocol\/otaf020","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T12:09:09Z","timestamp":1742731749000},"source":"Crossref","is-referenced-by-count":7,"title":["Clinical Outcomes for Patients With Ulcerative Colitis in Cases of Withdrawal and Resumption of Janus Kinase Inhibitors: Multicenter Cohort Study"],"prefix":"10.1093","volume":"7","author":[{"given":"Yasuki","family":"Sano","sequence":"first","affiliation":[{"name":"Third Department of Internal Medicine, Division of Gastroenterology and Hepatology, Kansai Medical University , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Ito","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Division of Gastroenterology and Hepatology, Kansai Medical University , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Yagi","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Division of Gastroenterology and Hepatology, Kansai Medical University , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9601-4065","authenticated-orcid":false,"given":"Yusuke","family":"Honzawa","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Division of Gastroenterology and Hepatology, Kansai Medical University , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimasa","family":"Fukata","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Division of Gastroenterology and Hepatology, Kansai Medical University , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4244-3243","authenticated-orcid":false,"given":"Makoto","family":"Naganuma","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Division of Gastroenterology and Hepatology, Kansai Medical University , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,22]]},"reference":[{"issue":"18","key":"2025041411512494000_CIT0001","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med."},{"issue":"10292","key":"2025041411512494000_CIT0002","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet."},{"issue":"10341","key":"2025041411512494000_CIT0003","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet."},{"issue":"4","key":"2025041411512494000_CIT0004","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med."},{"issue":"6","key":"2025041411512494000_CIT0005","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1002\/ueg2.12584","article-title":"Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure","volume":"12","author":"Pan\u00e9s","year":"2024","journal-title":"United European Gastroenterol J"},{"issue":"6","key":"2025041411512494000_CIT0006","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S2468-1253(21)00062-5","article-title":"Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial","volume":"6","author":"Kobayashi","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"2025041411512494000_CIT0007","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020","volume":"56","author":"Nakase","year":"2021","journal-title":"J Gastroenterol."},{"issue":"5","key":"2025041411512494000_CIT0008","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"issue":"11","key":"2025041411512494000_CIT0009","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1093\/ecco-jcc\/jjab065","article-title":"Efficacy and safety of tofacitinib re-treatment for ulcerative colitis after treatment interruption: results from the OCTAVE clinical trials","volume":"15","author":"Pan\u00e9s","year":"2021","journal-title":"J Crohns Colitis."},{"issue":"1","key":"2025041411512494000_CIT0010","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1093\/ecco-jcc\/jjad123","article-title":"Withdrawal and re-treatment with filgotinib in ulcerative colitis: post hoc analyses of the phase 2b\/3 SELECTION and SELECTIONLTE studies","volume":"18","author":"Vermeire","year":"2024","journal-title":"J Crohns Colitis."},{"issue":"2","key":"2025041411512494000_CIT0011","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/jgh.16386","article-title":"Early recapture of response with tofacitinib 10\u00a0mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE Sustain","volume":"39","author":"Allegretti","year":"2024","journal-title":"J Gastroenterol Hepatol."},{"issue":"2","key":"2025041411512494000_CIT0012","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1093\/ecco-jcc\/jjad104","article-title":"Major adverse cardiovascular events by baseline cardiovascular risk in patients with ulcerative colitis treated with tofacitinib: data from the OCTAVE clinical programme","volume":"17","author":"Schreiber","year":"2023","journal-title":"J Crohns Colitis."},{"issue":"2","key":"2025041411512494000_CIT0013","doi-asserted-by":"publisher","first-page":"499","DOI":"10.5217\/ir.2018.16.2.233","article-title":"Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies [published correction appears in Intest Res]","volume":"16","author":"Motoya","year":"2018","journal-title":"Intest Res."},{"issue":"10","key":"2025041411512494000_CIT0014","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1093\/ibd\/izy131","article-title":"Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib","volume":"24","author":"Winthrop","year":"2018","journal-title":"Inflamm Bowel Dis."},{"issue":"10","key":"2025041411512494000_CIT0015","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1111\/jgh.15923","article-title":"Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open","volume":"37","author":"Matsuoka","year":"2022","journal-title":"J Gastroenterol Hepatol."},{"issue":"1","key":"2025041411512494000_CIT0016","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/ibd\/izac063","article-title":"Long-term risk of herpes zoster infection in patients with ulcerative colitis receiving tofacitinib","volume":"29","author":"Winthrop","year":"2023","journal-title":"Inflamm Bowel Dis."},{"issue":"Apr","key":"2025041411512494000_CIT0017","doi-asserted-by":"publisher","first-page":"152362","DOI":"10.1016\/j.semarthrit.2024.152362","article-title":"Continued JAK inhibitor treatment on the risk of recurrent herpes zoster reactivation in patients with immune-mediated inflammatory diseases: a nationwide population-based study in South Korea","volume":"65","author":"Kim","year":"2024","journal-title":"Semin Arthritis Rheum."},{"issue":"2","key":"2025041411512494000_CIT0018","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s12325-023-02732-6","article-title":"Safety of upadacitinib in immune-mediated inflammatory diseases: systematic literature review of indirect and direct treatment comparisons of randomized controlled trials","volume":"41","author":"Mysler","year":"2024","journal-title":"Adv Ther."},{"issue":"1","key":"2025041411512494000_CIT0019","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/ecco-jcc\/jjaa145","article-title":"Tofacitinib in ulcerative colitis: real-world evidence from the ENEIDA Registry","volume":"15","author":"Chaparro","year":"2021","journal-title":"J Crohns Colitis."},{"issue":"9","key":"2025041411512494000_CIT0020","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/apt.17674","article-title":"Integrated safety analysis of filgotinib for ulcerative colitis: results from SELECTION and SELECTIONLTE [published correction appears in Aliment Pharmacol Ther]","volume":"58","author":"Schreiber","year":"2023","journal-title":"Aliment Pharmacol Therap"},{"issue":"10","key":"2025041411512494000_CIT0021","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s40264-024-01454-0","article-title":"Pregnancy outcomes in patients treated with upadacitinib: analysis of data from clinical trials and postmarketing reports","volume":"47","author":"Mahadevan","year":"2024","journal-title":"Drug Saf."},{"issue":"5","key":"2025041411512494000_CIT0022","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.cgh.2019.07.054","article-title":"Significance of conducting 2 types of fecal tests in patients with ulcerative colitis","volume":"18","author":"Naganuma","year":"2020","journal-title":"Clin Gastroenterol Hepatol."}],"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otaf020\/62524008\/otaf020.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/7\/2\/otaf020\/62524008\/otaf020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/7\/2\/otaf020\/62524008\/otaf020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T11:51:32Z","timestamp":1744631492000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otaf020\/8090468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,22]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otaf020","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,3,22]]},"article-number":"otaf020"}}